Doxorubicin HCL INJ 50 MG

Doxorubicin has ability to bind to DNA and inhibit Nuclec’c acid synthesis, rapid cell penetration and paranucleolar chromatin binding. Doxorubicin is indicated to regression in neoplastic conditions such as acute Leukemia, Wilm’s tumour, Neuroblastoma, soft tissue and bone sarcomas, breast carcinoma.